Tharimmune

Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions

placeBridgewater, New Jersey, United States calendar_todayFounded 2023 groups1 employees language tharimmune.com

Registered entities

Social engagement

Social engagement: 1.9K social following, 9 posts in the last 12 months — top quartile of its industry.

Investor mix

27 investors on record; lead investors include SDS Capital Group, Gravitas Capital, DRW Trading Group, Liberty City Ventures.

Investor typeCountShare
Venture capital311%
Angel & family office14%
Other / undisclosed2385%

Recent activity

23 Jun 2026
Product launch
Canton Strategic Holdings locking service
18 Jun 2026
Milestone
regulatory
17 Jun 2026
Event
CC Builders Forum
Coming soon